Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
subutinib maleate
- Development stage
- Phase 1
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Subutinib maleate is an investigational, orally bioavailable small molecule multi-targeted tyrosine kinase inhibitor (TKI) developed by Chia Tai Tianqing Pharmaceutical Group. It is designed for the treatment of advanced solid tumors by inhibiting signaling pathways essential for tumor angiogenesis and cell proliferation. As a derivative of sunitinib, it targets several receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and the proto-oncogene c-Kit. The drug has been evaluated in Phase I clinical trials (such as NCT01806376) to establish its safety profile, maximum tolerated dose, and pharmacokinetic characteristics in patients with refractory or advanced malignancies.
- Other names
- subutinib
02
Targets
PDGFRB (Platelet-derived growth factor receptor beta)VEGFR (VEGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on subutinib maleate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on subutinib maleate.